Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 10;16(3):483-486.
doi: 10.1021/acsmedchemlett.5c00034. eCollection 2025 Mar 13.

Structural Studies of the Dopamine D4 Receptor Antagonist Sonepiprazole as an Inhibitor of Human Carbonic Anhydrases

Affiliations

Structural Studies of the Dopamine D4 Receptor Antagonist Sonepiprazole as an Inhibitor of Human Carbonic Anhydrases

Andrea Angeli et al. ACS Med Chem Lett. .

Abstract

In this study, we provide the first evidence that sonepiprazole, a dopamine D4 receptor antagonist, acts as a potent inhibitor of human carbonic anhydrases (hCAs). Sonepiprazole exhibited significant inhibitory activity across the panel of catalytically active hCAs, with the exception of hCA IV, and hCA III. The most potent inhibition was observed against the brain-associated isoform hCA VII, with a K I of 2.9 nM. Insights from X-ray crystallographic structures of the complexes with hCA I, hCA II, and hCA XII revealed that the sulfonamide group of sonepiprazole coordinates the zinc ion in the active site, a typical interaction for this class of inhibitors. Despite the presence of isoform-specific residues at the rim of the active site pocket, these variations seem not to significantly impact the compound overall inhibition potency. These findings highlight a dual functionality of sonepiprazole as both a D4 receptor antagonist and a carbonic anhydrase inhibitor.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Similar articles

References

    1. Beaulieu J. M.; Gainetdinov R. R. The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev. 2011, 63, 182–217. 10.1124/pr.110.002642. - DOI - PubMed
    1. Giorgioni G.; Del Bello F.; Pavletić P.; Quaglia W.; Botticelli L.; Cifani C.; Micioni Di Bonaventura E.; Micioni Di Bonaventura M. V.; Piergentili A. Recent findings leading to the discovery of selective dopamine D4 receptor ligands for the treatment of widespread diseases. Eur. J. Med. Chem. 2021, 212, 11314110.1016/j.ejmech.2020.113141. - DOI - PubMed
    1. Vallone D.; Picetti R.; Borrelli E. Structure and function of dopamine receptors. Neurosci Biobehav Rev. 2000, 24, 125–132. 10.1016/S0149-7634(99)00063-9. - DOI - PubMed
    1. Perrault G.; Depoortere R.; Morel E.; Sanger D. J.; Scatton B. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J. Pharmacol. Exp. Ther. 1997, 280, 73–82. 10.1016/S0022-3565(24)36394-3. - DOI - PubMed
    1. Grattan V.; Vaino A. R.; Prensky Z.; Hixon M. S. Antipsychotic Benzamides Amisulpride and LB-102 Display Polypharmacy as Racemates, S Enantiomers Engage Receptors D2 and D3, while R Enantiomers Engage 5-HT7. ACS Omega. 2019, 4, 14151–14154. 10.1021/acsomega.9b02144. - DOI - PMC - PubMed

LinkOut - more resources